Piper Sandler raised the firm’s price target on Hinge Health (HNGE) to $71 from $70 and keeps an Overweight rating on the shares. The firm notes the company reported strong Q3 results last night, with revenue and adjusted operating income exceeding the high end of guidance. The revenue beat was driven by yield and flowed through to adjusted operating income at a 93.4% incremental margin. Hinge guided Q4 ahead of consensus and raised the 2025 outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health price target raised to $65 from $61 at Canaccord
- Hinge Health price target raised to $65 from $62 at Barclays
- Hinge Health Reports Strong Q3 2025 Financial Results
- Hinge Health: Strong Financial Performance and Growth Potential Amidst Rising Demand for Digital MSK Solutions
- Hinge Health reports Q3 EPS (2c) vs 1c last year